Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
naNO-DENGUE: Phase I Peptide Vaccine for Dengue
NCT04935801Phase 1Completed
- Sponsor
- Gylden Pharma
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LD PepGNP-Dengue in dengue fever (4 arms), sponsored by Gylden Pharma. Primary endpoints: Solicited local & Systemic Adverse Events at 14 days, Unsolicited Adverse Events at 180 days and 4 more. Started Aug 2021; status: completed.
02
Drugs
LD PepGNP-Dengue
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT04935801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935801.